A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

Liver International

Volumn 37, Issue 8, 2017, Pages 1157-1166

  Cabibbo, Giuseppe ^a   Petta, Salvatore ^a   Barbàra, Marco ^a   Missale, Gabriele ^b   Virdone, Roberto ^c   Caturelli, Eugenio ^d   Piscaglia, Fabio ^e   Morisco, Filomena ^f   Colecchia, Antonio ^g   Farinati, Fabio ^h   Giannini, Edoardo ⁱ   Trevisani, Franco ^j   Craxì, Antonio ^a   Colombo, Massimo ^k   Cammà, Calogero ^a   Bucci, Laura ^l   Zoli, Marco ^l   Garuti, Francesca ^l   Lenzi, Barbara ^l   Biselli, Maurizio ^l   Caraceni, Paolo ^l   Cucchetti, Alessandro ^l   Gramenzi, Annagiulia ^l   Granito, Alessandro ^l   Magalotti, Donatella ^l   Serra, Carla ^l   Negrini, Giulia ^l   Napoli, Lucia ^l   Salvatore, Veronica ^l   Benevento, Francesca ^l   Benvegnù, Luisa ^l   Gazzola, Alessia ^l   Murer, Francesca ^l   Pozzan, Caterina ^l   Vanin, Veronica ^l   Moscatelli, Alessandro ^l   Pellegatta, Gaia ^l   Picciotto, Antonino ^l   Savarino, Vincenzo ^l   Ciccarese, Francesca ^l   Del Poggio, Paolo ^l   Olmi, Stefano ^l   de Matthaeis, Nicoletta ^l   Balsamo, Mariella Di Marco Claudia ^l   Vavassori, Elena ^l   Roselli, Paola ^l   Dell’Isola, Serena ^l   Ialungo, Anna Maria ^l   Rastrelli, Elena ^l   Attardo, Simona ^l   Rossi, Margherita ^l   Costantino, Andrea ^l   Affronti, Andrea ^l   Affronti, Marco ^l   Mascari, Marta ^l   Felder, Martina ^l   Mega, Andrea ^l   Gasbarrini, Antonio ^l   Pompili, Maurizio ^l   Rinninella, Emanuele ^l   Sacco, Rodolfo ^l   Mismas, Valeria ^l   Foschi, Francesco Giuseppe ^l   Dall’Aglio, Anna Chiara ^l   Feletti, Valentina ^l   Lanzi, Arianna ^l   Cappa, Federica Mirici ^l   Neri, Elga ^l   Stefanini, Giuseppe Francesco ^l   Tamberi, Stefano ^l   Olivani, Andrea ^l   Biasini, Elisabetta ^l   Nardone, Gerardo ^l   Guarino, Maria ^l   Svegliati Baroni, Gialuca ^l   Ortolani, Alessio ^l   Masotto, Alberto ^l   Marchetti, Fabiana ^l   Valerio, Matteo ^l   Marra, Fabio ^l   Aburas, Sami ^l   Inghilesi, Andrea L ^l   Cappelli, Alberta ^l   Golfieri, Rita ^l   Mosconi, Cristina ^l   Renzulli, Matteo ^l   Coccoli, Piero ^l   Zamparelli, Marco Sanduzzi ^l   more..

^a DIBIMIS   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Ospedali Riuniti Villa Sofia Cervello   (Italy)

^d BELCOLLE HOSPITAL   (Italy)

^e Division of Internal Medicine   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Department of Medical and Surgical Sciences   (Italy)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^l NONE

more..

Author keywords

hepatocellular carcinoma; prognosis; recurrences; survival

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN;

ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY CANCER; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR VOLUME; COMPLICATION; EPIDEMIOLOGY; LIVER TUMOR; META ANALYSIS; MORTALITY; TUMOR RECURRENCE; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 85011632597     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13357     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Hepatobiliary Cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 2015: 1–114.
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
4. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.
5. Cabibbo G, Reig M, Gadaleta-Caldarola G, et al. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1. Future Oncol. 2016;12:281–284.
6. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
7. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.
8. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–858.
9. Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16:2931–2942.
10. Zhuang L, Zeng X, Yang Z, et al. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361.
11. Zhang W, Song TQ, Zhang T, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–1134.
12. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
13. Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65:719–726.
14. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
15. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–232.
16. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.
17. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:71–75.
18. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–1554.
19. Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res. 2001;20:301–311.
20. Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–1559.
21. Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative adiofrequency ablation. A matched case-control study. Oncology. 2007;72(Suppl. 1):132–138.
22. Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol. 2007;13:5343–5350.
23. Yamanaka Y, Shiraki K, Miyashita K, et al. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. World J Gastroenterol. 2005;11:2174–2178.
24. Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197–1204.
25. Petta S, Cabibbo G, Barbara M, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther. 2017;45:160–168.
26. Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33:2521–2537.
27. Earle CC, Pham B, Wells GA. An assessment of methods to combine published survival curves. Med Decis Making. 2000;20:104–111.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
29. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274–1283.
30. Maida M, Orlando E, Cammà C, et al. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014;20:4141–4150.
31. Villa E, Colantoni A, Cammà C, et al. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol. 2003;21:441–446.
32. Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2016;65:861–869.
33. Iwadou S, Nouso K, Kuwaki K, et al. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int. 2010;30:1027–1032.
34. Kim SU, Jung KS, Lee S, et al. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34:1008–1017.
35. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for hepatocellular carcinoma early recurrence: much ado about nothing. J Hepatol. 2016;65:861–862.
36. Vale CL, Tierney JF, Stewart LA. Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol. 2002;31:107–111.
37. Jeng GT, Scott JR, Burmeister LF. A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage. JAMA 1995;274:830–836.